Ogeda

About Ogeda

Ogeda is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda’s orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase II clinical development for the treatment of women’s health disorders. Ogeda has additional small molecules targeting GPCRs in preclinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vesalius Biocapital, Fund+ and SRIW.